New MS Drug Yields Mixed Results in Study

Relapse rates with daclizumab were lower than with a standard therapy, but side effects were greater

HealthDay news image

Source: HealthDay
Related MedlinePlus Pages: Medicines, Multiple Sclerosis

Leave a Comment